The Filing Desk

Inovio Pharmaceuticals vs Serina Therapeutics

Inovio Pharmaceuticals INO · Serina Therapeutics SER · Pharmaceuticals

Inovio Pharmaceuticals reported revenue of $0 million in fiscal 2025, about the same as Serina Therapeutics' $0 million in fiscal 2025. Inovio Pharmaceuticals' revenue fell 70.0% in its latest year, and Serina Therapeutics' grew 132.1%. Inovio Pharmaceuticals had an operating margin of -132871.3%, against -18478.5% at Serina Therapeutics. Free cash flow was −$89 million at Inovio Pharmaceuticals and −$18 million at Serina Therapeutics.

Side by side

Inovio PharmaceuticalsSerina Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$0M$0M
Revenue growth−70.0%132.1%
Revenue growth a year, last 5 years−57.7%−24.2%
Gross margin——
Operating margin−132,871.3%−18,478.5%
Net margin−130,000.0%−14,755.4%
Free cash flow−$89M−$18M
Free cash flow margin−136,074.5%−13,856.9%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count72.6%38.5%
Last close$1.71$1.20
P/E at the last close——
Insider trades, last 12 months—bought $77,955, sold $335,128
Piotroski F-score0 of 82 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Inovio PharmaceuticalsSerina Therapeutics
Operating margin
Percent of revenue
Inovio PharmaceuticalsSerina Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Inovio PharmaceuticalsSerina Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Inovio Pharmaceuticals and Serina Therapeutics pages.